Mass Spectrometry for ADC Characterization: What You Really Need to Know for IND Filing
Antibody-drug conjugates are among the most analytically complex molecules in the biopharmaceutical pipeline. They sit at the intersection of large-molecule and small-molecule chemistry — and that complexity shows up clearly at the regulatory stage. When teams first approach IND filing for an ADC, one of the most common questions I hear is: "How much MS data do we actually need?"
The honest answer is nuanced. FDA doesn't prescribe a checklist of mass spectrometry experiments for IND. But what they do expect is a scientifically sound understanding of your molecule — and for an ADC, mass spectrometry is the cornerstone of that understanding. Getting this wrong, or doing too little too late, is one of the most common causes of IND hold letters and CMC deficiencies I've seen in practice.
Here's what you need to know.
Why ADCs Are Analytically Unique
A conventional monoclonal antibody is already complex. An ADC is a heterogeneous mixture of conjugates — each molecule carrying a different number of drug payloads (your drug-to-antibody ratio, or DAR), potentially at different conjugation sites, with a linker that introduces its own chemical complexity. On top of that, you have unconjugated antibody, free drug, and aggregated or degraded species to contend with.
This heterogeneity is not a flaw — it's inherent to how most ADCs are made. But it means that standard UV-based or chromatographic methods alone will not give you a complete picture. Mass spectrometry uniquely allows you to resolve and quantify this mixture in ways that no other technique can.
The Core MS Characterization Package for IND
For an IND filing, your MS characterization package should, at minimum, address these questions:
1. What is the average DAR and drug load distribution?
This is typically addressed using hydrophobic interaction chromatography (HIC) coupled with UV detection, but intact mass analysis by native MS or denaturing LC-MS provides orthogonal confirmation and a higher-resolution picture of the distribution. For cysteine-conjugated ADCs, you'll commonly report DAR 0, 2, 4, 6, and 8 species. For site-specific ADCs, the picture is simpler and cleaner — which is one of the analytical advantages of that format.
Average DAR is a critical quality attribute (CQA) that directly impacts both efficacy and safety. FDA will expect you to define it, control it, and monitor it through your release testing.
2. Where is the drug conjugated?
Peptide mapping with LC-MS/MS is your primary tool here. For cysteine conjugation, you're confirming the expected interchain disulfide cysteines are the sites of modification. For lysine conjugation, the picture is more complex and you should be prepared to characterize the distribution of conjugation sites, even if you cannot control to a specific site. For engineered site-specific ADCs, confirming site fidelity is especially important — and is something FDA will look at closely.
At IND, you don't need an exhaustive positional breakdown for every lot, but you do need to demonstrate you understand where the drug is going.
3. What is the intact mass of the conjugate?
Intact mass analysis by LC-MS (electrospray ionization with deconvolution) confirms the overall molecular composition of your ADC. This serves as a high-level identity and purity check — confirming you have the correct heavy and light chain masses, the expected glycosylation profile, and no large-scale unexpected modifications.
For many ADCs, this is done at the intact level and at the subunit level (after IdeS digestion, for example) to allow better mass resolution of the Fc, Fab, and conjugated Fab arms separately.
4. Are there any unexpected modifications or degradation products?
This is where MS earns its keep as a developability and stability tool, not just a characterization tool. Peptide mapping should be designed to detect:
Deamidation and oxidation (standard for any biologic)
Linker hydrolysis or premature drug release
Payload-related modifications (some payloads are reactive under certain conditions)
Succinimide ring opening (particularly relevant for maleimide-linked ADCs)
For IND, your forced degradation and stress study data should be supported by MS to identify the identity of degradation products and confirm whether they are payload-related.
What FDA Is Actually Looking For
FDA's expectations for ADC characterization at IND are laid out across multiple guidance documents — including the 2022 ICH S9 guidance, FDA's own ADC-specific guidance (still evolving), and the broader CMC guidance for biologics. The overarching expectation is **a fit-for-purpose characterization package** that is commensurate with the stage of development.
At IND, this means:
You understand what your molecule is and how it behaves
You've identified your CQAs (DAR, drug load distribution, conjugation site consistency, aggregation, free drug) and have a preliminary justification for why they matter
Your analytical methods are capable of detecting changes in these attributes
Your release and stability specifications are science-based, even if not fully justified yet
What it does not mean is that every MS method needs to be fully validated. Qualification is typically sufficient at IND. Full validation can be deferred to BLA.
Common Mistakes I See
Relying solely on HIC for DAR. HIC is a great method, but it can miss certain conjugate species and doesn't give you direct molecular weight information. A native MS or intact LC-MS experiment to confirm DAR orthogonally is worth the investment.
Undercharacterizing the linker-payload. Teams sometimes focus so heavily on the antibody portion that the linker-payload chemistry gets insufficient attention. The linker stability and its role in PK/PD is increasingly a focus area for FDA reviewers.
No MS on stressed samples. If you haven't looked at your ADC by peptide mapping after temperature stress or oxidative stress, you don't know what's degrading or where. This is exactly the kind of information that shows up as a question in your IND review.
Not tying MS data to CQAs. Data without interpretation is just data. Each MS experiment should be clearly connected to a quality attribute and a clinical/biological rationale for why it matters.
A Practical Starting Point
If you're early in ADC development and building out your IND analytical package, here's a reasonable minimum MS characterization scope:
Intact LC-MS — identity and average DAR confirmation
Subunit LC-MS (post-IdeS or post-reduction) — resolution of conjugated species and glycosylation
Native MS or HIC-MS — drug load distribution and DAR species quantification
Peptide mapping with LC-MS/MS — conjugation site confirmation, sequence coverage, PTM identification
Peptide mapping on stressed samples — degradation pathway identification
This is a starting package, not a complete one. As you move toward Phase 1 and beyond, you'll want to build out your comparability framework, add reference standard characterization, and develop the method lifecycle documentation that supports your BLA.
The Bottom Line
Mass spectrometry is not optional for ADC IND filing — it's foundational. The question isn't whether to include MS data, but whether your MS package tells a coherent scientific story about your molecule. FDA reviewers are increasingly sophisticated about ADC characterization, and gaps in your MS data will surface as questions.
The good news is that with a well-designed characterization strategy, you can build a strong IND package without over-investing at early stage. The key is knowing what questions your MS data needs to answer — and making sure it actually answers them.